US3545439A - Medicated devices and methods - Google Patents

Medicated devices and methods Download PDF

Info

Publication number
US3545439A
US3545439A US696011A US3545439DA US3545439A US 3545439 A US3545439 A US 3545439A US 696011 A US696011 A US 696011A US 3545439D A US3545439D A US 3545439DA US 3545439 A US3545439 A US 3545439A
Authority
US
United States
Prior art keywords
female
resilient
ring
medication
predetermined period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US696011A
Inventor
Gordon W Duncan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of US3545439A publication Critical patent/US3545439A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/08—Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception, e.g. combined with devices protecting against contagion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Definitions

  • This invention relates to pharmaceutical devices and methods of their use, more particularly to sucha device for intravaginal placement in the form of a resilient medicated ring comprised of acompatible nonabsorable polymeric material and an effective amount of a diffusible medicament.
  • the invention relates also to methods of providing continuous medication, during a predetermined medication period via the vagina in female mammals, human and animal, for example dogs, sheep, cattle, horses, and rats.
  • the resilient annular device is formed of a compatible drug-permeable polymeric materiall
  • the word compatible means compatible both with the environment of the vaginal tract in that there is no break-' down of the annular tensile nature of the device due to the contents of the vagina, nor isthere any absorption of the polymeric material itself, only the medication being absorbed ing to known methods from polyisocyanate and polyhydroxyl material.
  • the .polyhydroxyl materials for example polyesters, polyethers and the like, are reacted with isocyanates to yield rubberlike products for use as millalble gums or in casting systems or as thermo processable res-ins. See U.S. Pat. Nos.
  • Another exemplary polymer is polyethylene, prepared by polymerization of ethylene, usually prepared from natural gas or the cracking of crude oil.
  • Modern Plastics Encyclopedia for 1968, Sept, 1967, Vol. 45, No. la Mc,Graw-Hill, New York, New York, U.S.A. describes the preparation of the aforesaid suitable plastic materials, especially in reference to their molding qualities, compression molding temperatures, and'compression molding pressures. Details on theaforesaid polymers are given in the plastic properties chart of the aforesaid Encyclopedia, pages 29 through 46, inclusive. In rcference-to'the nonabsorbability and nontoxic nature of the aforesaid polymeric material, U.S. Pat. No.
  • 3,272,204 refers to the use of vinyon N, nylon, orlon, dacron, teflon, and the like as nonabsorbable, reinforcing strands for the preparation ofprostheses'.
  • Such strands have the advantage that they do not become a pant of the body tissues. So it is with the improyed resilient annular device of the present invention, which is particularly advantageous because of its ready insertion and ready retentionbut does not become or form any part of the tissue of the female'mammal utilizing the device, for example human and animal, such as dogs, cattle,
  • the present annular device with its medication contained therein for continued medication as desired, is greatly superior to implantates, which of necessity are placed within the actual'body tissues, such placement often requiring at least minor surgery for both insertion and removal, especially if encapsulated-
  • the device properly sizedand fitted, is useful to provide a readily inserted, readily retained, and readily removable source of continued medication for local and systemic effects
  • Suitable drugs are triiodothyronine, isoproterenol, atropine, histamine, nitrogen mustard, vitamin B pyrimethamine, hormonal substances,
  • drogenic substances e.g., estradiol, progesterone, androstenedione, testosterone, cortisol, medroxyprogesterone acetate, melengestrol acetate, chlormadinone, and the like.
  • Pat. No. 3,279,996 describes various conventional silicone rubbers which may or may not contain fillers,sujch assilica, .to
  • compatible, drug-permeable polymeric materials are, for example, nylon, a polyamide'resin made by polymerization of the hexamethylenediamine salt of adipic acidydacron, a synthetic fiber made by E. I. DuPont deNer'nours and Co.
  • An in vitro method of test utilizes polymeric material, e.g., polysiloxane tubing which is loaded with the particular drug and plugged at the ends with polysiloxane cement. After allowing about 48 hours for setting or curing, the filled linlr of tubing is placed in, for example, 50 mlof normal saline in a suitable container and shaken at approximately body temperature for about 24 hours. Spectroscopic analysis of the liquid, for example by the isonicotinic hydrazide method for medroxyprogesterone acetate, shows that the drug is capable of permeating through the silastic into the saline material, in which it can be demonstrated by the in vitro test. For in vivo testing, placement of a suitable size device containing a known amount of medicaments, e.g., rnedroxyprogesterone acetate in a polysiloxane,
  • each of the annular devices is that sufficient from teraphthalic acid; and ethylene glycol; teflon, a
  • the device are as follows: digitoxin, 5 to 50 mg.; triiodothyronine, l to 10 mg.; isoproterenol, lOO mg. to 2 6m; atropine, 10 to 250 mg.; histamine, 1 to 10 mg.; nitrogen mustard, 50 mg. to 2 Gm.; vitamin B 0.5 to 100 mg; pyrimethamine, 50 mg. to l Gm.; estradiol, 0.5 to 100 mg.; progesterone, 50 mg. to 2 Gm.; androstenedione, 50 mg. to 2 6m; testosterone, 50 mg. to 2 Gm.; cortisol, 100 mg. to 2.5 Gm.; medroxyprogesterone acetate, 50 mg.
  • any additive medication for example locally effective antimicrobial agent, is calculated on the basis of the known amounts useful in similar vaginal applications.
  • Other principal active medicaments are, for example, antiulcer and antisecret ory agents, for example 'methscopolamine, 75mg. to 2 Gm.; anticoagulant, for example diphenadione, 75 mg. to l Gm; hypocholesteremic agent, for example 3methyl-5-isoxazole carboxylic acid, 200 mg. to 2 Gm.; appetite clepressant, for example D-amphetamine, l mg.
  • hypoglycemic agent l[[p-[2- (S-chloro-wanisamidokthyl]phenyl]sulfonyl]-3-cyclohexylurea, 100mg. to 2.5 Gm.
  • hypotensive agent mecamylamine, 100 mg.
  • antibacterial and antimalarial agents 7- deoxy-7(S)-chlorolincomycin, 2 to 7 0m, N-demethyl lincomycin, 2- to .7-Gm., 4 pentyl-N-'demethyl-7(S)-chlorolincomycin, l to 5.Gm.
  • antihypertensive agent for example angiotensin amide, 100 mg. to 2 Gm.
  • glucocorticoid for example dexamethasone, 10 to 250 mg.
  • prostaglandins for example PGE,, PGE PGA, as antiulcer and antisecretory agents and for inhibition of blood platelet stickiness, 0.5 to 10 mg.
  • the aforesaid amounts are ranges of active ingredients tobe included in the annular device, the exact amount depending upon the age, condition of the patient, and the particular effect desired. These amounts are calculated to provide predetermined daily release dosages as follows: for the cardiac stimulant digitoxin, 0.1 to 0.2 mg.; for the metabolic stimulant triiodothyronine, to 100 mcg.; for the bronchodilator isoproterenol, 5 to 30 mg.; for the antianemia agent vitamin B12, to 300 mcg.; for the antimalarial pyrimethamine, l to 5 mg.;' for the estrogen estradiol, 1 to 500 mcg.; for the progestogen progesterone, 0.1 to 20 mg; for the androgens androstenedione and testosterone, 0.1 to 10 mg.; for the glucocorticoid cortisol, 5 to 50 mg.; for the progestogens medroxyprogesterone acetate
  • antimalarial lincomycin compounds 250 to 500 mg., 250 to 500 mg. and 125 to 300 mg., respectively; for the angiotensin amide, 0.7 to 30 mg.; for the dexamethasone, 0.2 to 2 mg.; and for the prostaglandins, 1 to 10 mcg.
  • Especially beneficial progestational substances for use in this invention include, for example, norethynodrel, norethindrone, medroxyprogesterone acetate, chlormadinone acetate,
  • estrogenic substances for combination with these progestogens include,
  • ethinyl estradiol and 3-methyl ether of ethinyl esthe reproductive tract for example synivaginitis, endometriosis.
  • These devices are constructed in such a way that they are retained in the vagina for periods of a day up to several months and can be readily inserted and removed, for example in the case of the human female patient.
  • the device due to its unique shape and size, does not obstruct the os uteri as do diaphragms.
  • the medication for release as desired can be introduced into hollow cavities in the ring forming a tubular device, or directly introduced into the plastic material itself while the device is being manufactured as by molding.
  • the drug can be the individual drugor mixed with suitable compatible physiologic material, for example in the case of a progestogen an estrogen can be included.
  • suitable compatible physiologic material for example in the case of a progestogen an estrogen can be included.
  • a locally effective antimicrobial agent for example an antibiotic such as neomycin, nystatin and polymyxin can be included within the polymeric material.
  • the improved device of this invention possesses numerous advantages over, for example the intrauterine devices, which the uterus rejects in some cases. Moreover, nonprofessional placement of the present inventive device is possible in comparison with the intrauterine devices. Unexpected advantages for the improved device as such are ease of placement, ease of retention, ease of removal, relative freedom of infectious conditions, and ease of dosage over a wide range.
  • the amount of drug incorporated into the inventive device is that sufficient to bring about the local and/or systemic effect, for examplean effective amount for control of fertility, probably by inhibition of ovulation.
  • the medicated device of the present invention provides more uniform and constant serum levels of drug during the predetermined period of time for which the beneficial physiologic effects are desired. This-is in marked contrast to fluctuations that occur with other treatments, for example oral treatment. In thepractice of this invention, low circulating levels ofmedicament can still be highly effective in target tissues while not accumulating in the nontarget tissues.
  • the uterine tissue is the target in contrastto the heart, muscle, liver and like tissues, which are non'target tissues.
  • the improved ring device will vary in size, for example in the case of the human from about mm. diameter to about mm. diameter, these dimensions being overall dimensions; the diameter of the actual ring itself will be in the neighborhood of about 5 to 10 mm. In the case where an endless helical spring or flat spring structure is used for additional tensing property, the diameter of this metallic part of the ring will vary with that of the device itself.
  • Overall dimensions of the improved medicated ring for use in other species are approximately as follows: for sheep and swine, 20 to 65 mm.; for dogs, 5 to 50 mm.; for cats, 5 to 30 mm.; for cattle, 50 to mm.; and for horses, 50 to mm. These dimensions are overall dimensions.
  • the actual diameter of the ring itself varies with the overall size and with the particular species.
  • the annular devices may incorporate a tab for assistance in removal.
  • the polymeric materials are, as disclosed in the aforesaid Modern Plastics Encyclopedia, those that are suitable for molding in manners known to those familiar with this art.
  • Those polymeric materials for instance the organopolysiloxanes, which are in a liquid state or paste state, can be directly mixed with the drug, for example melengestrol acetate or medroxyprogesterone acetate, and the semifluid material placed into the mold for compression molding with the addition of a catalyst, for example stannous octoate.
  • a catalyst for example stannous octoate.
  • the device is to contain a spring structure for tension properties, this is usually centered in the semifluid material while it is in the mold and thereafter covered by additional drug-containing polymeric material for the compression molding.
  • An additional, in vivo, technique for determining the suitability of the polymeric material for use in the preparation of the inventive device is as follows: 150 mg. of medr'oxyprogesterone acetate was well mixed with 615 mg. of polysil oxane elastomer 3H2 382 (Dow Corning Company) to prepare resilient containers approximately 4 cm. long and 0.48 cm. in diameter. Different dosages of the drug are obtained by cutting the required length of the material. The material is sterilized and can be inserted subcutaneously into the scapular region of normally cycling female rats.
  • EXAMPLE 2 Resilient devices are prepared, each to contain 2 Gm. of medroxyprogesterone acetate, 3 drops of stannous octoate as catalyst, and q.s. silastic elastomer, medical grade 382 (Dow Corning Company).
  • Placement of a ring in the vaginal tract of the human female supplies an effective amount of medroxyprogesterone acetate for the control of fer tility by inhibition of ovulation.
  • Measurement of basal body temperature shows that ovulation did not occur during a 4 week test period.
  • Eimilar rings are prepared with other molds designed to give outside diameters of 70, and 75 mm., respectively. Although these annular ring structures will cure at room temperature in the presence-of the catalyst, for convenience and speed of handling, they are cured at temperatures of from about 40 to about 70 C.
  • Tensing means are added to the devices prepared as in Examplez by positioning within the first half of the mold an endless helical spring having a diameter of about 8 mm. and weighing approximately 4.8 Gm. The upper half of the mold is then sealed down with the use of the wing nuts and the device compression molded in a like manner at about 45 C.
  • EXAMPLE 4 Polyurethane rubber-type annular devices are prepared by polymerizing two equivalents of methylene bis isocyanate, one equivalent of 3,000 molecular weight polyether triol and one isocyanate, 1,000 of the trio] and 45 of the butanediol. At the time of mixing, melengestrol acetate to provide 2 Gm. per individual ring is added to the mixture. The mixture of drug and elastomer is then heat cured in the mold at about 100 for 1 hour to provide resilient annular devices for placing in the vaginal tract.
  • medicated annular devices containing an effective amount of the drug which can permeate through the polymeric substance are prepared from nylon, natural rubber, synthetic rubber, dacron, teflon, and polyethylene and are useful in the same manner inproviding continued sustained medication over desired predetermined periods of times in the vaginal tract of the female mammals.
  • the manner and process of making and using the invention is not limited to the aforesaid examples, :for the other desirable medicaments as heretofore listed can be incorporated into devices prepared from the various polymeric substances to provide sustained medication over predetermined periods of time.
  • the size of the device will vary to provide close anatomical contact with the vagina] or like tract of the female mammals.
  • the relationship between the daily amount of medication to provide a beneficial physiologic effect and the amount initially placed in the inventive annular device has been set forth for the individual drugs concerned, and within this concept the amount of drug is varied for the particular polymer, depending upon the permeability rate and the amount required for the physiological effect.
  • Devices so prepared are likewise beneficially effective in providing the desired medication via the vagina.
  • annular shaped device is preferred because of simplicity in manufacture and ease in fitting, insertion and removal, other shapes which will fit anatomically, will stay in place and still allow for ease of insertion and removal can be used, such asoval or elliptical shapes.
  • the device does not have to be in one plane if a closer anatomical fit is desired.
  • a medicated annular device in the form of a resilient individual ring which releases medication for systemic effects during intravaginal use in a female mammal consisting essentially of a medicament-permeable, compatible, nonabsorba ble, resilient, polymeric substance and a systemically effective amount of a diffusible medicament for providing to a said female mammal sustained systemic medication for a predetermined period of time.
  • the resilient individual ring of claim 1 wherein the polymeric substance is a polysiloxane or polyurethane elastomer.
  • the resilient individual ring of claim 1 which is a tubular ring.
  • a method of providing a predetermined amount of systemically effective medicament for a predetermined period of time to a female human which consists essentially of retainably positioning within the vaginal tract of a said female human for said predetermined period of time a resilient individual ring according to claim 2.
  • a method of providing a predetermined amount of systemically effective medicament for a predetermined period of time to a female human which consists essentially of retainably positioning within the vaginal tract of a said female human for said predetermined period of time a resilient individual ting according to claim 3.
  • a method of providing a predetermined amount of systemically effective medicament for a predetermined period of time to a female human which consists essentially of retainably positioning within the vaginal tract of a said female human for said predetermined-period of time a resilient individual ring according to claim 4.
  • a method of providing a predetermined amount of systemically effective medicament for a predetermined period of time to a female human which consists essentially of retainably positioning within the vaginal tract of a said female human for said predetermined period of time a resilient individual ring according to claim 5.
  • a method of providing a predetermined amount of systemically effective medicament for a predetermined period of time to a female mammal which consists essentially of retainably positioning within the vaginal tract of a said female mammal for said predetermined period of time a resilient individual ring according to claim 6.
  • a method of providing a predetermined amount of systemically effective medicament for a predetermined period of time to a female mammal which consists essentially of retainably positioning within the vaginal tract of. a said female mammal for said predetermined period of time a resilient individual ring according to claim 7.
  • a method of providing a predetermined amount of systemically effective fertility-inhibiting medicament for a predetermined period of time to a female mammal which consists essentially of retainably positioning within the vaginal tract of a said female mammal for said predetermined period of time a resilient individual ring according to claim 8.

Description

United States atent [72] Inventor Gordon W. Duncan 2,423,475 7/1947 Rice et a1 424/28 Kalamazoo, Michigan 3,442,266 5/1969 Krejciet a1. 128/130 [2]] App]. No. 696,011 3,055,297 9/1962 Leeds...... 424/28 [22] Wed 2 Primary Exuminer- Adele M. Eager [45] Pau :med Attorneys-Joseph K. Andonian, John Kekich and Edward G. [73] Assignee The Up ohn Company Jones Kalamazoo, Michigan a corporation of Delaware [54] MEDICATED DEVICES AND METHODS 19 clalms4nrawmg Flgs' ABSTRACT: An improved resilient annular device for in- [52] US. Cl 128/260, travaginal placement and retention as required and formed of 3/ 128/130 128/270 260/75 a compatible nonabsorbable polymeric substance such as an [51] Int. Cl A6lm 7/00 organopolysiloxane nylon, natural or Synthetic rubber, [50] Field of Search 128/130, dacron, teflon, polyurethane and polyethylene and containing 131, 128, 129,334, 270, 156, 268, 260, 1; 24/ an effective amount of a medicament which is capable of 27, 28; 264/337; 260/75, 858; 3/ passage through the drug-permeable polymeric material. The References Cited device is useful to provide a readily inserted, readily retained and readily removable source of continued medication for UNITED STATES PATENTS sustained beneficial effects in female mammals, human and 2,017,596 1/1936 Hoffman 424/28 animal.
. MEDICATED DEYICES ANDMETHODS BRIEF SUMMARY OF THE INVENTION This invention relates to pharmaceutical devices and methods of their use, more particularly to sucha device for intravaginal placement in the form of a resilient medicated ring comprised of acompatible nonabsorable polymeric material and an effective amount of a diffusible medicament. The invention relates also to methods of providing continuous medication, during a predetermined medication period via the vagina in female mammals, human and animal, for example dogs, sheep, cattle, horses, and rats.
BRIEF DESCRIPTION OF THE DRAWING DETAILED DESCRIPTION It has beenfound thatt he device according to this invention provides sufiiciently resilient characteristics so that upon tensing for ready manual or mechanical insertion in the vaginal tract there will be relative ease of handling. Upon 'releaseof tension, the device will resume the annular form necessary for providing retentive contact within the vaginal area. Proper retention is obtained upon placement in the vaginain accordance with FIG. 3 and when properly placed, the ring fits securely and comfortably between the rear wall of the vagina and the upper edge, of the pubic bone. In that position the medicated device can'be readily inserted and is readily retained during the desired period of continued medication. when it is desired that medication cease, the ring is readily removed in a reverse fashion to insertion.
'As aforesaid, "the resilient annular device is formed of a compatible drug-permeable polymeric materiall As used herein, the word compatible means compatible both with the environment of the vaginal tract in that there is no break-' down of the annular tensile nature of the device due to the contents of the vagina, nor isthere any absorption of the polymeric material itself, only the medication being absorbed ing to known methods from polyisocyanate and polyhydroxyl material. The .polyhydroxyl materials, for example polyesters, polyethers and the like, are reacted with isocyanates to yield rubberlike products for use as millalble gums or in casting systems or as thermo processable res-ins. See U.S. Pat. Nos. 2,87 1,218 and 3,015,650. Another exemplary polymer is polyethylene, prepared by polymerization of ethylene, usually prepared from natural gas or the cracking of crude oil. Modern Plastics Encyclopedia for 1968, Sept, 1967, Vol. 45, No. la,"Mc,Graw-Hill, New York, New York, U.S.A. describes the preparation of the aforesaid suitable plastic materials, especially in reference to their molding qualities, compression molding temperatures, and'compression molding pressures. Details on theaforesaid polymers are given in the plastic properties chart of the aforesaid Encyclopedia, pages 29 through 46, inclusive. In rcference-to'the nonabsorbability and nontoxic nature of the aforesaid polymeric material, U.S. Pat. No. 3,272,204 refers to the use of vinyon N, nylon, orlon, dacron, teflon, and the like as nonabsorbable, reinforcing strands for the preparation ofprostheses'. Such strands have the advantage that they do not become a pant of the body tissues. So it is with the improyed resilient annular device of the present invention, which is particularly advantageous because of its ready insertion and ready retentionbut does not become or form any part of the tissue of the female'mammal utilizing the device, for example human and animal, such as dogs, cattle,
and horses. In this respect, the present annular device, with its medication contained therein for continued medication as desired, is greatly superior to implantates, which of necessity are placed within the actual'body tissues, such placement often requiring at least minor surgery for both insertion and removal, especially if encapsulated- As aforesaid, the device, properly sizedand fitted, is useful to provide a readily inserted, readily retained, and readily removable source of continued medication for local and systemic effects Subject to the-property of being capable of passage through the polymeric material, a wide range of medication is suitable for use in this improved device for both local and systemic effects. Suitable drugs are triiodothyronine, isoproterenol, atropine, histamine, nitrogen mustard, vitamin B pyrimethamine, hormonal substances,
i.e., estrogenic substances, progestational substances, an-
drogenic substances, e.g., estradiol, progesterone, androstenedione, testosterone, cortisol, medroxyprogesterone acetate, melengestrol acetate, chlormadinone, and the like. In
forv local and systemic effects in the female mammals.
Likewise, there is nodeleterious action on the sensitive tissue in the area of placement in the vaginal tract. Widely varying types of polymeric material are suitable in providing these compatible, nontoxic and nonabsorbable properties, for exampleorganopolysiloxane of the linear type converted to rubber by heat curing (vulcanization). These linear organopolysiloxanes are known as the conventional type, for example dimethyloplysiloxane, Likewise suitable are those known as the RTV type which are converted to the rubbery stateat room temperature in the presence of a catalyst. U.S.
Pat. No. 3,279,996 describes various conventional silicone rubbers which may or may not contain fillers,sujch assilica, .to
enhance tensile strength and the other physical properties of the cured rubber. This patent also describes commercially available'RTV'silicone rubbers. Other patent literature shows the preparation of conventional silicone rubbers, illustratively U.S. ,Pats. Warwick, No. 2,504,137; Konkle et al., No. 2,890,188; andotherpatents set, forth, in the U.S. Pat. to Long et al., No. 3,279,966. Other suitable nontoxic, nonabsorbable,
compatible, drug-permeable polymeric materials, are, for example, nylon, a polyamide'resin made by polymerization of the hexamethylenediamine salt of adipic acidydacron, a synthetic fiber made by E. I. DuPont deNer'nours and Co.
this connection, both in vivo and invitro methods of determination of passage of the drug by diffusion through the drugpermeable polymeric material are available. See Dziuk, P. J. r and Cook,- B., Passage of Steroids Through Silicone Rubbers, Endocrinology, 78:208, 1966; U.S. Pat. No. 3,279,996; Folkman and Edmonds, Circulation Research 102632, 1962; Folkman and Long, J. Surg. Res. 43:139, 1964; Powers, 1. Parasitology51:53 (April 1965), No. 2 Section 2. An in vitro method of test utilizes polymeric material, e.g., polysiloxane tubing which is loaded with the particular drug and plugged at the ends with polysiloxane cement. After allowing about 48 hours for setting or curing, the filled linlr of tubing is placed in, for example, 50 mlof normal saline in a suitable container and shaken at approximately body temperature for about 24 hours. Spectroscopic analysis of the liquid, for example by the isonicotinic hydrazide method for medroxyprogesterone acetate, shows that the drug is capable of permeating through the silastic into the saline material, in which it can be demonstrated by the in vitro test. For in vivo testing, placement of a suitable size device containing a known amount of medicaments, e.g., rnedroxyprogesterone acetate in a polysiloxane,
of medication in each of the annular devices is that sufficient from teraphthalic acid; and ethylene glycol; teflon, a
tetrafluoroethylene polymer manufactured by E. l. DuPont de Nemoursand Co.; polyurethane elastomer prepared accordfor bringing about the desired physiologic effect, for example, the amount sufficient for controlling fertility. Given in ranges of active ingredients, suitable amounts for individual drugs in digitoxin,
the device are as follows: digitoxin, 5 to 50 mg.; triiodothyronine, l to 10 mg.; isoproterenol, lOO mg. to 2 6m; atropine, 10 to 250 mg.; histamine, 1 to 10 mg.; nitrogen mustard, 50 mg. to 2 Gm.; vitamin B 0.5 to 100 mg; pyrimethamine, 50 mg. to l Gm.; estradiol, 0.5 to 100 mg.; progesterone, 50 mg. to 2 Gm.; androstenedione, 50 mg. to 2 6m; testosterone, 50 mg. to 2 Gm.; cortisol, 100 mg. to 2.5 Gm.; medroxyprogesterone acetate, 50 mg. to 2 Gm.; melengestrol acetate, 50 mg. to 2 Gm.; chlormadinone, 50 mg. to 2 Gm. The amount of any additive medication, for example locally effective antimicrobial agent, is calculated on the basis of the known amounts useful in similar vaginal applications. Other principal active medicaments are, for example, antiulcer and antisecret ory agents, for example 'methscopolamine, 75mg. to 2 Gm.; anticoagulant, for example diphenadione, 75 mg. to l Gm; hypocholesteremic agent, for example 3methyl-5-isoxazole carboxylic acid, 200 mg. to 2 Gm.; appetite clepressant, for example D-amphetamine, l mg. to 2 Gml; tranquilizers and sedatives, thiothixene and haloperidol, 50 mg. to 2 6m; hypoglycemic agent, l[[p-[2- (S-chloro-wanisamidokthyl]phenyl]sulfonyl]-3-cyclohexylurea, 100mg. to 2.5 Gm.; hypotensive agent, mecamylamine, 100 mg. to 1.5 Gm; antibacterial and antimalarial agents, 7- deoxy-7(S)-chlorolincomycin, 2 to 7 0m, N-demethyl lincomycin, 2- to .7-Gm., 4 pentyl-N-'demethyl-7(S)-chlorolincomycin, l to 5.Gm.; antihypertensive agent, for example angiotensin amide, 100 mg. to 2 Gm.; glucocorticoid, for example dexamethasone, 10 to 250 mg.: prostaglandins, for example PGE,, PGE PGA, as antiulcer and antisecretory agents and for inhibition of blood platelet stickiness, 0.5 to 10 mg. The aforesaid amounts are ranges of active ingredients tobe included in the annular device, the exact amount depending upon the age, condition of the patient, and the particular effect desired. These amounts are calculated to provide predetermined daily release dosages as follows: for the cardiac stimulant digitoxin, 0.1 to 0.2 mg.; for the metabolic stimulant triiodothyronine, to 100 mcg.; for the bronchodilator isoproterenol, 5 to 30 mg.; for the antianemia agent vitamin B12, to 300 mcg.; for the antimalarial pyrimethamine, l to 5 mg.;' for the estrogen estradiol, 1 to 500 mcg.; for the progestogen progesterone, 0.1 to 20 mg; for the androgens androstenedione and testosterone, 0.1 to 10 mg.; for the glucocorticoid cortisol, 5 to 50 mg.; for the progestogens medroxyprogesterone acetate, melengestrol acetate, and chlormadinone, 0.01 to 10 mg.; for the methscopolamine, 3 to 20 mg.; for the diphenadione, 3 to 5 mg.; for the 3-methyl-5- isoxazole carboxylic acid, l0 to 30 mg.; for rl-amphetamine, 5 to 30 mg.; for thiothixene, 2 to 30 mg.; for haloperidol, 2 to mg.; for the hypoglycemic cyclohexylurea compound, 5 to 50 mg.; for the mecamylamine, 2 to 10 mg.; for the antibacterial,
antimalarial lincomycin compounds, 250 to 500 mg., 250 to 500 mg. and 125 to 300 mg., respectively; for the angiotensin amide, 0.7 to 30 mg.; for the dexamethasone, 0.2 to 2 mg.; and for the prostaglandins, 1 to 10 mcg.
Especially beneficial progestational substances for use in this invention include, for example, norethynodrel, norethindrone, medroxyprogesterone acetate, chlormadinone acetate,
dimethisterone, and ,ethynodiol diacetate. Useful estrogenic substances for combination with these progestogens include,
for example, ethinyl estradiol and 3-methyl ether of ethinyl esthe reproductive tract, for example synivaginitis, endometriosis. These devices are constructed in such a way that they are retained in the vagina for periods of a day up to several months and can be readily inserted and removed, for example in the case of the human female patient. The device, due to its unique shape and size, does not obstruct the os uteri as do diaphragms. The medication for release as desired can be introduced into hollow cavities in the ring forming a tubular device, or directly introduced into the plastic material itself while the device is being manufactured as by molding. The drug can be the individual drugor mixed with suitable compatible physiologic material, for example in the case of a progestogen an estrogen can be included. Likewise, a locally effective antimicrobial agent, for example an antibiotic such as neomycin, nystatin and polymyxin can be included within the polymeric material. The improved device of this invention possesses numerous advantages over, for example the intrauterine devices, which the uterus rejects in some cases. Moreover, nonprofessional placement of the present inventive device is possible in comparison with the intrauterine devices. Unexpected advantages for the improved device as such are ease of placement, ease of retention, ease of removal, relative freedom of infectious conditions, and ease of dosage over a wide range. As aforesaid, the amount of drug incorporated into the inventive device is that sufficient to bring about the local and/or systemic effect, for examplean effective amount for control of fertility, probably by inhibition of ovulation. The medicated device of the present invention provides more uniform and constant serum levels of drug during the predetermined period of time for which the beneficial physiologic effects are desired. This-is in marked contrast to fluctuations that occur with other treatments, for example oral treatment. In thepractice of this invention, low circulating levels ofmedicament can still be highly effective in target tissues while not accumulating in the nontarget tissues. For example in the case of estradiol, the uterine tissue is the target in contrastto the heart, muscle, liver and like tissues, which are non'target tissues.
Depending upon the anatomy of the particular species. involved, the improved ring device will vary in size, for example in the case of the human from about mm. diameter to about mm. diameter, these dimensions being overall dimensions; the diameter of the actual ring itself will be in the neighborhood of about 5 to 10 mm. In the case where an endless helical spring or flat spring structure is used for additional tensing property, the diameter of this metallic part of the ring will vary with that of the device itself. Overall dimensions of the improved medicated ring for use in other species are approximately as follows: for sheep and swine, 20 to 65 mm.; for dogs, 5 to 50 mm.; for cats, 5 to 30 mm.; for cattle, 50 to mm.; and for horses, 50 to mm. These dimensions are overall dimensions. As will be apparent, the actual diameter of the ring itself varies with the overall size and with the particular species. Suitably the annular devices may incorporate a tab for assistance in removal. The polymeric materials are, as disclosed in the aforesaid Modern Plastics Encyclopedia, those that are suitable for molding in manners known to those familiar with this art. Those polymeric materials, for instance the organopolysiloxanes, which are in a liquid state or paste state, can be directly mixed with the drug, for example melengestrol acetate or medroxyprogesterone acetate, and the semifluid material placed into the mold for compression molding with the addition of a catalyst, for example stannous octoate. In case the device is to contain a spring structure for tension properties, this is usually centered in the semifluid material while it is in the mold and thereafter covered by additional drug-containing polymeric material for the compression molding.
An additional, in vivo, technique for determining the suitability of the polymeric material for use in the preparation of the inventive device is as follows: 150 mg. of medr'oxyprogesterone acetate was well mixed with 615 mg. of polysil oxane elastomer 3H2 382 (Dow Corning Company) to prepare resilient containers approximately 4 cm. long and 0.48 cm. in diameter. Different dosages of the drug are obtained by cutting the required length of the material. The material is sterilized and can be inserted subcutaneously into the scapular region of normally cycling female rats. Daily records of vaginal cytology, which reflect the release'of the medroxyprogesterone acetate, are made for periods of 2 to 6 weeks at dosages of 18.75 .mg. for 6 weeks in four animals, 37.5 mg. for 2 weeks in four animals, and 56.25 mg. for 2 weeks in four animals. Cycling is prevented in the otherwise normally cycling female rats. This shows that the active medicament is released by diffusion through the drugpermeable polymer and exerts its physiological effect via the vaginal tract. in addition to the in vivo data in the rats, it was found by measuring the final content of the medicament in the silastic material that average total releases of 4.4 mg., 5 mg. and 5.2 mg. occurred from elastomeric carrier material of 0,5, 1.0 and 1.5 cm. in size, respectively.
The following examples illustrate the manner and process of making and using the inventive annular device, but are not to be construed as limiting. i it EXAMPLE 1 An annular device was 'prepared of organopolysiloxane elastomer containing 170 mg. of medroxyprogesterone acetate. The ring was placed in accordance with the technique of this invention in the vaginal tract of a monkey and allowed to remain there for 63 days. At the end of this time, the residual content of the medicament in the ring was found by analysis to be l32 mg., showing that a sufficient amount for control of fertility was released from the ring during its retention within the vaginal tract.
EXAMPLE 2 Resilient devices are prepared, each to contain 2 Gm. of medroxyprogesterone acetate, 3 drops of stannous octoate as catalyst, and q.s. silastic elastomer, medical grade 382 (Dow Corning Company).
12.85 Gm. of medroxyprogesterone.acetate are thoroughly mixed into 92.15 Gm. dimetliylpolysiloxane elastomer, medical grade 382 (Dow Corning Company). 21 Gms. of this mixture plus 3 drops of catalyst, stannous octoate, is incorporated into each mold designed to prepare a device of an outside diameter of about 80 mm. The two halves of the mold are tightened down bythe use of wing nuts and the mold is allowed to cure in an oven of 40 to 50 C. for l to 2 hours. Each so prepared ring weighs about 17 Gm. and contains about 2 Gm. of the medroxyprogesterone acetate. Placement of a ring in the vaginal tract of the human female supplies an effective amount of medroxyprogesterone acetate for the control of fer tility by inhibition of ovulation. Measurement of basal body temperature shows that ovulation did not occur during a 4 week test period.
Eimilar rings are prepared with other molds designed to give outside diameters of 70, and 75 mm., respectively. Although these annular ring structures will cure at room temperature in the presence-of the catalyst, for convenience and speed of handling, they are cured at temperatures of from about 40 to about 70 C.
Tensing means are added to the devices prepared as in Examplez by positioning within the first half of the mold an endless helical spring having a diameter of about 8 mm. and weighing approximately 4.8 Gm. The upper half of the mold is then sealed down with the use of the wing nuts and the device compression molded in a like manner at about 45 C.
EXAMPLE 4 Polyurethane rubber-type annular devices are prepared by polymerizing two equivalents of methylene bis isocyanate, one equivalent of 3,000 molecular weight polyether triol and one isocyanate, 1,000 of the trio] and 45 of the butanediol. At the time of mixing, melengestrol acetate to provide 2 Gm. per individual ring is added to the mixture. The mixture of drug and elastomer is then heat cured in the mold at about 100 for 1 hour to provide resilient annular devices for placing in the vaginal tract.
EXAMPLE 5 Likewise, medicated annular devices containing an effective amount of the drug which can permeate through the polymeric substance are prepared from nylon, natural rubber, synthetic rubber, dacron, teflon, and polyethylene and are useful in the same manner inproviding continued sustained medication over desired predetermined periods of times in the vaginal tract of the female mammals.
The manner and process of making and using the invention is not limited to the aforesaid examples, :for the other desirable medicaments as heretofore listed can be incorporated into devices prepared from the various polymeric substances to provide sustained medication over predetermined periods of time. As aforesaid, depending upon the particular species in which the device is to be used, the size of the device will vary to provide close anatomical contact with the vagina] or like tract of the female mammals. The relationship between the daily amount of medication to provide a beneficial physiologic effect and the amount initially placed in the inventive annular device has been set forth for the individual drugs concerned, and within this concept the amount of drug is varied for the particular polymer, depending upon the permeability rate and the amount required for the physiological effect. Devices so prepared are likewise beneficially effective in providing the desired medication via the vagina.
Although an annular shaped device is preferred because of simplicity in manufacture and ease in fitting, insertion and removal, other shapes which will fit anatomically, will stay in place and still allow for ease of insertion and removal can be used, such asoval or elliptical shapes. The device does not have to be in one plane if a closer anatomical fit is desired.
lclaim:
1. A medicated annular device in the form of a resilient individual ring which releases medication for systemic effects during intravaginal use in a female mammal consisting essentially of a medicament-permeable, compatible, nonabsorba ble, resilient, polymeric substance and a systemically effective amount of a diffusible medicament for providing to a said female mammal sustained systemic medication for a predetermined period of time.
2. The resilient individual ring of claim 1 wherein the polymeric substance is a polysiloxane or polyurethane elastomer.
3. The resilient individual ring of claim 2 wherein the polysiloxane is convertible to a rubbery state by heat curing or by room temperature in the presence of a catalyst.
4. The resilient individual ring of claim 2 wherein the polysiloxane is an organopolysiloxane 5. The resilient individual ring of claim 4 wherein the organopolysiloxane is dimethylpolysiloxane.
6. The resilient individual ring of claim 1 which is a tubular ring.
7. The resilient individual ring of claim 1 which contains tension providing means.
8. The resilient individual ring of claim 1 wherein the diffusible medicament is effective for systemic inhibition of fertility of said female mammal.
9. The resilient individual ring of claim 5 wherein the dimethylpolysiloxane is convertible to a rubbery state at room temperature in the presence of a catalyst and the diffusibie medicament is medroxyprogesterone acetate.
10. A method of providing a predetermined amount of systemically effective medicament for a predetermined period of time to a female mammal, which consists essentially of equivalent of I ,d butnnediol. Parts by weight are 250 of the 7 retain-ably positioning within the vaginal tract of a said female 7 mammal for said predetermined period of time a resilient individual ring according to claim 1.
11. A method of providing a predetermined amount of systemically effective medicament for a predetermined period of time to a female human, which consists essentially of retainably positioning within the vaginal tract of a said female human for said predetermined period of time a resilient individual ring according to claim 2.
12. A method of providing a predetermined amount of systemically effective medicament for a predetermined period of time to a female human, which consists essentially of retainably positioning within the vaginal tract of a said female human for said predetermined period of time a resilient individual ting according to claim 3.
13. A method of providing a predetermined amount of systemically effective medicament for a predetermined period of time to a female human, which consists essentially of retainably positioning within the vaginal tract of a said female human for said predetermined-period of time a resilient individual ring according to claim 4.
14. A method of providing a predetermined amount of systemically effective medicament for a predetermined period of time to a female human, which consists essentially of retainably positioning within the vaginal tract of a said female human for said predetermined period of time a resilient individual ring according to claim 5.
15. A method of providing a predetermined amount of systemically effective medicament for a predetermined period of time to a female mammal, which consists essentially of retainably positioning within the vaginal tract of a said female mammal for said predetermined period of time a resilient individual ring according to claim 6.
A method of providing a predetermined amount of systemically effective medicament for a predetermined period of time to a female mammal, which consists essentially of retainably positioning within the vaginal tract of. a said female mammal for said predetermined period of time a resilient individual ring according to claim 7. r
17. A method of providing a predetermined amount of systemically effective fertility-inhibiting medicament for a predetermined period of time to a female mammal, which consists essentially of retainably positioning within the vaginal tract of a said female mammal for said predetermined period of time a resilient individual ring according to claim 8.
18. A method of providing a predetermined amount of medroxyprogesterone acetate for a predetermined period of time to a female human, which consists essentially of retainably positioning within the vaginal tract of a said female human for said predetermined period of time a resilient individual ring according to claim 9.
19. The method of claim 10 wherein the ring is removed at the end of said predetermined period of time.
US696011A 1968-01-04 1968-01-04 Medicated devices and methods Expired - Lifetime US3545439A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69601168A 1968-01-04 1968-01-04

Publications (1)

Publication Number Publication Date
US3545439A true US3545439A (en) 1970-12-08

Family

ID=24795343

Family Applications (1)

Application Number Title Priority Date Filing Date
US696011A Expired - Lifetime US3545439A (en) 1968-01-04 1968-01-04 Medicated devices and methods

Country Status (14)

Country Link
US (1) US3545439A (en)
JP (1) JPS5125677B1 (en)
BE (1) BE726454A (en)
BR (1) BR6905338D0 (en)
CA (1) CA985173A (en)
CH (1) CH554172A (en)
DE (1) DE1900196A1 (en)
ES (1) ES360946A1 (en)
FR (1) FR1604934A (en)
GB (1) GB1252021A (en)
GT (1) GT196811877A (en)
MY (1) MY7500059A (en)
NL (1) NL6818655A (en)
SE (1) SE369375B (en)

Cited By (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3645258A (en) * 1969-04-08 1972-02-29 Charis Aka Charilaos George Ma Intrauterine device
US3656483A (en) * 1970-01-15 1972-04-18 Biolog Concepts Inc Intrauterine medicator
US3809076A (en) * 1971-06-16 1974-05-07 I Chabon Intrauterine contraceptive device
US3814097A (en) * 1972-02-14 1974-06-04 Ici Ltd Dressing
US3844285A (en) * 1969-08-28 1974-10-29 Commw Scient Ind Res Org Device for administration to ruminants
US3851648A (en) * 1973-10-11 1974-12-03 Mead Johnson & Co Zero-order release device
US3854476A (en) * 1973-04-05 1974-12-17 R Dickinson Intra-vaginal device and method
US3880991A (en) * 1969-03-24 1975-04-29 Brook David E Polymeric article for dispensing drugs
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3888975A (en) * 1972-12-27 1975-06-10 Alza Corp Erodible intrauterine device
US3892238A (en) * 1971-09-16 1975-07-01 Abbott Lab Drug supporting anchor
US3901232A (en) * 1973-10-26 1975-08-26 Alza Corp Integrated device for administering beneficial drug at programmed rate
US3911911A (en) * 1969-06-16 1975-10-14 Reese Hospital Michael Anti-fertility device
US3924622A (en) * 1973-10-11 1975-12-09 Mead Johnson & Co Zero-order release method
US3946106A (en) * 1974-10-24 1976-03-23 G. D. Searle & Co. Microsealed pharmaceutical delivery device
US3948263A (en) * 1974-08-14 1976-04-06 Minnesota Mining And Manufacturing Company Ballistic animal implant
US3973560A (en) * 1973-07-27 1976-08-10 A. H. Robins Company, Incorporated Intrauterine device of C or omega form
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
US3991760A (en) * 1975-12-02 1976-11-16 The Procter & Gamble Company Vaginal medicament dispensing means
US3992518A (en) * 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
US3995633A (en) * 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US3996933A (en) * 1972-10-02 1976-12-14 Morton Gutnick Intrauterine contraceptive devices and processes
US4012497A (en) * 1974-09-24 1977-03-15 Schering Aktiengesellschaft Drug excipient of silicone rubber
US4014987A (en) * 1974-06-04 1977-03-29 Alza Corporation Device for delivery of useful agent
US4016251A (en) * 1972-08-17 1977-04-05 Alza Corporation Vaginal drug dispensing device
US4018220A (en) * 1974-07-19 1977-04-19 Lionel C. R. Emmett Method of insertion for intrauterine device of C or omega form with tubular inserter
US4024871A (en) * 1975-07-23 1977-05-24 Ethicon, Inc. Antimicrobial sutures
US4031886A (en) * 1975-09-11 1977-06-28 Morhenn Vera B Occlusive pessary
US4043339A (en) * 1976-02-02 1977-08-23 The Upjohn Company Method of and vaginal insert for prostaglandin administration
US4053580A (en) * 1975-01-01 1977-10-11 G. D. Searle & Co. Microsealed pharmaceutical delivery device
US4093490A (en) * 1977-04-29 1978-06-06 Ortho Pharmaceutical Corporation Method of making vaginal diaphragm
US4102998A (en) * 1972-10-02 1978-07-25 Morton Gutnick Process for the prevention of venereal disease
US4111196A (en) * 1973-07-27 1978-09-05 Lionel C. R. Emmett Intrauterine contraceptive device of c or omega form with tubular inserter and method of placement
DE2818934A1 (en) * 1977-04-29 1978-11-09 Ortho Pharma Corp VAGINAL DIAPHRAGM AND METHOD OF MANUFACTURING THEREOF
US4155991A (en) * 1974-10-18 1979-05-22 Schering Aktiengesellschaft Vaginal ring
US4191741A (en) * 1978-09-22 1980-03-04 Eli Lilly And Company Removable drug implant
EP0010987A1 (en) * 1978-11-07 1980-05-14 Beecham Group Plc Device for oral administration to a ruminant animal
US4215691A (en) * 1978-10-11 1980-08-05 Alza Corporation Vaginal contraceptive system made from block copolymer
US4237885A (en) * 1978-10-23 1980-12-09 Alza Corporation Delivery system with mated members for storing and releasing a plurality of beneficial agents
US4250611A (en) * 1979-04-19 1981-02-17 Alza Corporation Process for making drug delivery device with reservoir
US4264576A (en) * 1979-06-28 1981-04-28 Eli Lilly And Company Contraceptive methods and compositions
US4264578A (en) * 1979-07-16 1981-04-28 Eli Lilly And Company Contraceptive methods and compositions
US4264575A (en) * 1979-07-16 1981-04-28 Eli Lilly And Company Contraceptive methods and compositions
US4264577A (en) * 1979-08-03 1981-04-28 Eli Lilly And Company Contraceptive methods and compositions
US4292965A (en) * 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
US4310510A (en) * 1976-12-27 1982-01-12 Sherman Kenneth N Self administrable anti-fertility composition
US4326510A (en) * 1979-11-20 1982-04-27 World Health Organization Barrier contraceptive torus
EP0050867A1 (en) * 1980-10-28 1982-05-05 Schering Aktiengesellschaft Vaginal ring
US4344431A (en) * 1969-03-24 1982-08-17 University Of Delaware Polymeric article for dispensing drugs
US4402695A (en) * 1980-01-21 1983-09-06 Alza Corporation Device for delivering agent in vagina
US4469671A (en) * 1983-02-22 1984-09-04 Eli Lilly And Company Contraceptive device
US4589880A (en) * 1983-07-14 1986-05-20 Southern Research Institute Disposable spermicide-releasing diaphragm
US4629449A (en) * 1982-07-29 1986-12-16 Alza Corporation Vaginal dispenser for dispensing beneficial hormone
US4690683A (en) * 1985-07-02 1987-09-01 Rutgers, The State University Of New Jersey Transdermal varapamil delivery device
US4816257A (en) * 1985-09-20 1989-03-28 Research & Education Institute, Harbor-Ucla Medical Center Inc. Method for producing an in vivo environment suitable for human embryo transfer
US4985253A (en) * 1985-10-11 1991-01-15 Sumitomo Pharmaceuticals Company, Limited Sustained release composition for pharmaceutical substances comprising a silicone elastomer carrier
US5002540A (en) * 1989-05-22 1991-03-26 Warren Kirschbaum Intravaginal device and method for delivering a medicament
US5146931A (en) * 1988-08-15 1992-09-15 Kurz Karl Heinz Device to be placed in the uterus
US5181505A (en) * 1989-03-08 1993-01-26 Lew Chel W Method and apparatus for delivery of a medicament in the oral cavity
US5224493A (en) * 1991-01-30 1993-07-06 Cadco Corporation Contraceptive intracervical device and novel nonsystemic agents for the prevention of conception and disease
US5269321A (en) * 1991-01-16 1993-12-14 Controlled Therapeutics (Scotland) Ltd. Retrievable pessary
WO1995000118A1 (en) * 1993-06-17 1995-01-05 Leiras Oy Intra-uterine ring for the release of an active agent, such as a hormone, and an introducer
WO1995009641A1 (en) * 1993-10-01 1995-04-13 Lectin Biopharma, Inc. Using lectins for contraception, prophylaxis and therapy
US5422118A (en) * 1986-11-07 1995-06-06 Pure Pac, Inc. Transdermal administration of amines with minimal irritation and high transdermal flux rate
LT3455B (en) 1993-06-17 1995-10-25 Leiras Oy Intravaginal delivery system of active agent
WO1996019196A1 (en) * 1994-12-19 1996-06-27 Galen (Chemicals) Limited INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS
WO1997040776A1 (en) * 1996-05-01 1997-11-06 Dec International Nz Limited Synchronising of animal oestrus and intra vaginal devices useful therein
US5788980A (en) * 1995-11-01 1998-08-04 Roussel Uclaf Intravaginal drug delivery device
US5972372A (en) * 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
US6039968A (en) * 1997-06-24 2000-03-21 Hoechst Marion Roussel Intravaginal drug delivery device
EP1159957A2 (en) 1996-12-02 2001-12-05 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Device for the local administration of solid or semi-solid formulations, sustained release formulations for parenteral administration and process of preparation
US6361780B1 (en) * 1998-11-12 2002-03-26 Cardiac Pacemakers, Inc. Microporous drug delivery system
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US20030093136A1 (en) * 2001-11-09 2003-05-15 Osypka Thomas P. Cardiac lead with steroid eluting ring
US6758840B2 (en) 2000-04-20 2004-07-06 Metris Therapeutics Limited Drug delivery device
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US20040265355A1 (en) * 2003-06-26 2004-12-30 Shalaby Shalaby W. Composite absorbable/biodegradable rings for controlled drug delivery
US20050042292A1 (en) * 2002-03-27 2005-02-24 Brendan Muldoon Intravaginal matrix drug delivery devices
US20050148995A1 (en) * 2003-12-29 2005-07-07 Kimberly-Clark Worldwide, Inc. Anatomically conforming vaginal insert
US20060270640A1 (en) * 2004-02-18 2006-11-30 Mercian Corporation Method of preventing, medicating, and/or treating hypocalcemia of domestic mammal
US20060280771A1 (en) * 2003-05-23 2006-12-14 Akzo Nobel N.V. Drug delivery system
EP1768625A2 (en) * 2004-07-09 2007-04-04 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators
US20070191320A1 (en) * 1998-12-10 2007-08-16 Nexmed Holdings, Inc. Methods of treatment for female sexual arousal disorder
US20070196433A1 (en) * 2003-04-29 2007-08-23 The Massachusetts General Hospital Corporation Methods and devices for the sustained release of multiple drugs
US20070254014A1 (en) * 2006-03-20 2007-11-01 Ahmed Salah U Flexible, compressed intravaginal rings, methods of making and using the same, and apparatus for making the same
US20080051740A1 (en) * 2006-06-16 2008-02-28 Family Health International Vaginal drug delivery system and method
US20090081278A1 (en) * 2007-09-21 2009-03-26 N.V. Organon Drug Delivery System
US20090202612A1 (en) * 2008-02-04 2009-08-13 Ahmed Salah U Monolithic Intravaginal Rings Comprising Progesterone and Methods of Making and Uses Thereof
EP2246062A1 (en) 2005-07-19 2010-11-03 The Population Council, Inc. Methods and compositions for emergency contraception using endothelin receptor antagonists
CN101977651A (en) * 2008-01-25 2011-02-16 犹他大学研究基金会 Linear order release polymer
US20110236462A1 (en) * 2010-03-28 2011-09-29 Shaked Ze Ev Intravaginal drug delivery device
EP2641602A1 (en) 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
US20130324380A1 (en) * 2012-06-04 2013-12-05 Caryn M. Horsley Medical exercise device
JP2013543763A (en) * 2010-11-12 2013-12-09 ザ ユニバーシティ オブ ユタ リサーチ ファウンデーション Intravaginal device for controlled delivery of lubricant
US8715712B2 (en) 2011-09-14 2014-05-06 Forsight Vision5, Inc. Ocular insert apparatus and methods
US8753667B2 (en) 2009-07-21 2014-06-17 The Population Council, Inc. Multi-layered gradient vaginal ring
WO2014167510A2 (en) 2013-04-10 2014-10-16 Preglem Sa Progesteron receptor modulators for use in the therapy of uterine fibroids
WO2015055789A1 (en) 2013-10-17 2015-04-23 Bayer Pharma Aktiengesellschaft INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION
US9084717B2 (en) 2003-06-26 2015-07-21 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
US9095744B2 (en) * 2012-06-04 2015-08-04 Caryn M. Horsley Medical exercise device
WO2016054002A1 (en) * 2014-09-29 2016-04-07 Yale University Progesterone impregnated vaginal ring/pessary
US9421126B2 (en) 2009-06-03 2016-08-23 Forsight Vision5, Inc. Anterior segment drug delivery
US9566267B2 (en) 2008-05-20 2017-02-14 Poly-Med, Inc. Biostable, multipurpose, microbicidal intravaginal devices
US9750636B2 (en) 2012-10-26 2017-09-05 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
WO2019084469A1 (en) 2017-10-27 2019-05-02 Renovia Inc. Devices, systems, and methods for training pelvic floor muscles
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
US10596103B2 (en) 2013-12-11 2020-03-24 Merek Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
USD935018S1 (en) * 2020-04-07 2021-11-02 The Population Council, Inc. Contraceptive
US11224602B2 (en) 2015-04-13 2022-01-18 Forsight Vision5, Inc. Ocular insert composition of a semi-crystalline or crystalline pharmaceutically active agent
WO2023200974A1 (en) 2022-04-14 2023-10-19 Yale University Nanoparticles and nanoparticle-releasing vaginal rings

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788505A (en) * 1972-09-05 1973-03-07 Moyer Dean L DEVICE AND METHOD FOR THE USE OF AN IRRITANT-TOXIC, ANTIPALUDEEN OR ANTIAMIBIAN MEDICINAL PRODUCT
US4300544A (en) * 1978-09-05 1981-11-17 Dia-Sert Corp. Disposable female contraceptive
GB8403360D0 (en) * 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
NL8600250A (en) * 1986-02-01 1987-09-01 Fundatech Sa VAGINAL ANTI-CONCEPTION AGENT.
DE3774101D1 (en) * 1987-01-15 1991-11-28 Fortune Capital Management Pessar.
GB8819477D0 (en) * 1988-08-16 1988-09-21 Wellcome Found Medicaments
EP1313422B1 (en) * 2000-08-24 2010-01-20 Sidney Lerner Non-hormonal vaginal contraceptive
US20100040671A1 (en) * 2008-08-12 2010-02-18 Ahmed Salah U Intravaginal Devices With a Rigid Support, Methods of Making, and Uses Thereof

Cited By (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4344431A (en) * 1969-03-24 1982-08-17 University Of Delaware Polymeric article for dispensing drugs
US3880991A (en) * 1969-03-24 1975-04-29 Brook David E Polymeric article for dispensing drugs
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3645258A (en) * 1969-04-08 1972-02-29 Charis Aka Charilaos George Ma Intrauterine device
US3911911A (en) * 1969-06-16 1975-10-14 Reese Hospital Michael Anti-fertility device
US3844285A (en) * 1969-08-28 1974-10-29 Commw Scient Ind Res Org Device for administration to ruminants
US3656483A (en) * 1970-01-15 1972-04-18 Biolog Concepts Inc Intrauterine medicator
US3809076A (en) * 1971-06-16 1974-05-07 I Chabon Intrauterine contraceptive device
US3892238A (en) * 1971-09-16 1975-07-01 Abbott Lab Drug supporting anchor
US3814097A (en) * 1972-02-14 1974-06-04 Ici Ltd Dressing
US4016251A (en) * 1972-08-17 1977-04-05 Alza Corporation Vaginal drug dispensing device
US3996933A (en) * 1972-10-02 1976-12-14 Morton Gutnick Intrauterine contraceptive devices and processes
US4102998A (en) * 1972-10-02 1978-07-25 Morton Gutnick Process for the prevention of venereal disease
US3888975A (en) * 1972-12-27 1975-06-10 Alza Corp Erodible intrauterine device
US3854476A (en) * 1973-04-05 1974-12-17 R Dickinson Intra-vaginal device and method
US3973560A (en) * 1973-07-27 1976-08-10 A. H. Robins Company, Incorporated Intrauterine device of C or omega form
US4111196A (en) * 1973-07-27 1978-09-05 Lionel C. R. Emmett Intrauterine contraceptive device of c or omega form with tubular inserter and method of placement
US3924622A (en) * 1973-10-11 1975-12-09 Mead Johnson & Co Zero-order release method
US3851648A (en) * 1973-10-11 1974-12-03 Mead Johnson & Co Zero-order release device
US3901232A (en) * 1973-10-26 1975-08-26 Alza Corp Integrated device for administering beneficial drug at programmed rate
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
US4014987A (en) * 1974-06-04 1977-03-29 Alza Corporation Device for delivery of useful agent
US4018220A (en) * 1974-07-19 1977-04-19 Lionel C. R. Emmett Method of insertion for intrauterine device of C or omega form with tubular inserter
US3948263A (en) * 1974-08-14 1976-04-06 Minnesota Mining And Manufacturing Company Ballistic animal implant
US4012497A (en) * 1974-09-24 1977-03-15 Schering Aktiengesellschaft Drug excipient of silicone rubber
US4155991A (en) * 1974-10-18 1979-05-22 Schering Aktiengesellschaft Vaginal ring
US3992518A (en) * 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
DE2547378A1 (en) * 1974-10-24 1976-04-29 Searle & Co DEVICE WITH LOCKED MICROCHAMBERS FOR DISPENSING A MEDICINAL PRODUCT
US3946106A (en) * 1974-10-24 1976-03-23 G. D. Searle & Co. Microsealed pharmaceutical delivery device
US4053580A (en) * 1975-01-01 1977-10-11 G. D. Searle & Co. Microsealed pharmaceutical delivery device
US4024871A (en) * 1975-07-23 1977-05-24 Ethicon, Inc. Antimicrobial sutures
US4031886A (en) * 1975-09-11 1977-06-28 Morhenn Vera B Occlusive pessary
US3995633A (en) * 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US3991760A (en) * 1975-12-02 1976-11-16 The Procter & Gamble Company Vaginal medicament dispensing means
US4043339A (en) * 1976-02-02 1977-08-23 The Upjohn Company Method of and vaginal insert for prostaglandin administration
US4310510A (en) * 1976-12-27 1982-01-12 Sherman Kenneth N Self administrable anti-fertility composition
US4093490A (en) * 1977-04-29 1978-06-06 Ortho Pharmaceutical Corporation Method of making vaginal diaphragm
DE2818934A1 (en) * 1977-04-29 1978-11-09 Ortho Pharma Corp VAGINAL DIAPHRAGM AND METHOD OF MANUFACTURING THEREOF
US4191741A (en) * 1978-09-22 1980-03-04 Eli Lilly And Company Removable drug implant
US4215691A (en) * 1978-10-11 1980-08-05 Alza Corporation Vaginal contraceptive system made from block copolymer
US4237885A (en) * 1978-10-23 1980-12-09 Alza Corporation Delivery system with mated members for storing and releasing a plurality of beneficial agents
EP0010987A1 (en) * 1978-11-07 1980-05-14 Beecham Group Plc Device for oral administration to a ruminant animal
US4292965A (en) * 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
US4250611A (en) * 1979-04-19 1981-02-17 Alza Corporation Process for making drug delivery device with reservoir
US4264576A (en) * 1979-06-28 1981-04-28 Eli Lilly And Company Contraceptive methods and compositions
US4264575A (en) * 1979-07-16 1981-04-28 Eli Lilly And Company Contraceptive methods and compositions
US4264578A (en) * 1979-07-16 1981-04-28 Eli Lilly And Company Contraceptive methods and compositions
US4264577A (en) * 1979-08-03 1981-04-28 Eli Lilly And Company Contraceptive methods and compositions
US4326510A (en) * 1979-11-20 1982-04-27 World Health Organization Barrier contraceptive torus
US4402695A (en) * 1980-01-21 1983-09-06 Alza Corporation Device for delivering agent in vagina
EP0050867A1 (en) * 1980-10-28 1982-05-05 Schering Aktiengesellschaft Vaginal ring
US4629449A (en) * 1982-07-29 1986-12-16 Alza Corporation Vaginal dispenser for dispensing beneficial hormone
US4469671A (en) * 1983-02-22 1984-09-04 Eli Lilly And Company Contraceptive device
US4589880A (en) * 1983-07-14 1986-05-20 Southern Research Institute Disposable spermicide-releasing diaphragm
US4690683A (en) * 1985-07-02 1987-09-01 Rutgers, The State University Of New Jersey Transdermal varapamil delivery device
US4816257A (en) * 1985-09-20 1989-03-28 Research & Education Institute, Harbor-Ucla Medical Center Inc. Method for producing an in vivo environment suitable for human embryo transfer
US4985253A (en) * 1985-10-11 1991-01-15 Sumitomo Pharmaceuticals Company, Limited Sustained release composition for pharmaceutical substances comprising a silicone elastomer carrier
US5422118A (en) * 1986-11-07 1995-06-06 Pure Pac, Inc. Transdermal administration of amines with minimal irritation and high transdermal flux rate
US5146931A (en) * 1988-08-15 1992-09-15 Kurz Karl Heinz Device to be placed in the uterus
US5181505A (en) * 1989-03-08 1993-01-26 Lew Chel W Method and apparatus for delivery of a medicament in the oral cavity
US5002540A (en) * 1989-05-22 1991-03-26 Warren Kirschbaum Intravaginal device and method for delivering a medicament
US5269321A (en) * 1991-01-16 1993-12-14 Controlled Therapeutics (Scotland) Ltd. Retrievable pessary
US5224493A (en) * 1991-01-30 1993-07-06 Cadco Corporation Contraceptive intracervical device and novel nonsystemic agents for the prevention of conception and disease
WO1995000118A1 (en) * 1993-06-17 1995-01-05 Leiras Oy Intra-uterine ring for the release of an active agent, such as a hormone, and an introducer
LT3455B (en) 1993-06-17 1995-10-25 Leiras Oy Intravaginal delivery system of active agent
WO1995009641A1 (en) * 1993-10-01 1995-04-13 Lectin Biopharma, Inc. Using lectins for contraception, prophylaxis and therapy
WO1996019196A1 (en) * 1994-12-19 1996-06-27 Galen (Chemicals) Limited INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS
US5855906A (en) * 1994-12-19 1999-01-05 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of 17β-oestradiol precursors
EP0776659B1 (en) * 1995-11-01 2002-04-10 Aventis Pharma S.A. Delivery device for medicaments by the intravaginal route
US5788980A (en) * 1995-11-01 1998-08-04 Roussel Uclaf Intravaginal drug delivery device
GB2328161A (en) * 1996-05-01 1999-02-17 Dec International Nz Limited Synchronising of animal oestrus and intra vaginal devices useful therein
US6423039B1 (en) 1996-05-01 2002-07-23 Interag Synchronizing of animal oestrus and intra vaginal devices useful therein
GB2328161B (en) * 1996-05-01 2000-09-27 Dec International Nz Limited Synchronising of animal oestrus and intra vaginal devices useful therein
US6663608B2 (en) 1996-05-01 2003-12-16 Interag Synchronizing of animal oestrus and intra vaginal devices useful therein
WO1997040776A1 (en) * 1996-05-01 1997-11-06 Dec International Nz Limited Synchronising of animal oestrus and intra vaginal devices useful therein
US5972372A (en) * 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
US6126958A (en) * 1996-07-31 2000-10-03 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
EP1159957A2 (en) 1996-12-02 2001-12-05 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Device for the local administration of solid or semi-solid formulations, sustained release formulations for parenteral administration and process of preparation
US6039968A (en) * 1997-06-24 2000-03-21 Hoechst Marion Roussel Intravaginal drug delivery device
US6361780B1 (en) * 1998-11-12 2002-03-26 Cardiac Pacemakers, Inc. Microporous drug delivery system
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US20070191320A1 (en) * 1998-12-10 2007-08-16 Nexmed Holdings, Inc. Methods of treatment for female sexual arousal disorder
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6758840B2 (en) 2000-04-20 2004-07-06 Metris Therapeutics Limited Drug delivery device
US7187980B2 (en) 2001-11-09 2007-03-06 Oscor Inc. Cardiac lead with steroid eluting ring
US6671562B2 (en) 2001-11-09 2003-12-30 Oscor Inc. High impedance drug eluting cardiac lead
US20030093136A1 (en) * 2001-11-09 2003-05-15 Osypka Thomas P. Cardiac lead with steroid eluting ring
US9993424B2 (en) 2002-03-27 2018-06-12 Allergan Pharmaceuticals International Limited Intravaginal matrix drug delivery devices
US20050042292A1 (en) * 2002-03-27 2005-02-24 Brendan Muldoon Intravaginal matrix drug delivery devices
US7883718B2 (en) 2003-04-29 2011-02-08 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
US7838024B2 (en) 2003-04-29 2010-11-23 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
US20080286339A1 (en) * 2003-04-29 2008-11-20 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and devices for the sustained release of multiple drugs
US7833545B2 (en) 2003-04-29 2010-11-16 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
US20070196433A1 (en) * 2003-04-29 2007-08-23 The Massachusetts General Hospital Corporation Methods and devices for the sustained release of multiple drugs
US7829112B2 (en) 2003-04-29 2010-11-09 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
US20090274654A1 (en) * 2003-04-29 2009-11-05 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and devices for the sustained release of multiple drugs
US20090060982A1 (en) * 2003-04-29 2009-03-05 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and devices for the sustained release of multiple drugs
US20080286322A1 (en) * 2003-04-29 2008-11-20 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and devices for the sustained release of multiple drugs
US20080248017A1 (en) * 2003-04-29 2008-10-09 Massachusetts Institute Of Technology Methods and devices for the sustained release of multiple drugs
US20130078286A1 (en) * 2003-05-23 2013-03-28 Msd Oss B.V. Drug delivery system
US8858977B2 (en) * 2003-05-23 2014-10-14 Merck Sharp & Dohme B.V. Drug delivery system
US8333983B2 (en) * 2003-05-23 2012-12-18 Msd Oss B.V. Drug delivery system
US20060280771A1 (en) * 2003-05-23 2006-12-14 Akzo Nobel N.V. Drug delivery system
US9370574B2 (en) 2003-06-26 2016-06-21 Poly-Med, Inc. Composite absorbable/biodegradable rings for controlled drug delivery
US9084717B2 (en) 2003-06-26 2015-07-21 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
US8404272B2 (en) * 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
US20040265355A1 (en) * 2003-06-26 2004-12-30 Shalaby Shalaby W. Composite absorbable/biodegradable rings for controlled drug delivery
US8217219B2 (en) 2003-12-29 2012-07-10 Kimberly-Clark Worldwide, Inc. Anatomically conforming vaginal insert
US20050148995A1 (en) * 2003-12-29 2005-07-07 Kimberly-Clark Worldwide, Inc. Anatomically conforming vaginal insert
US8506543B2 (en) 2003-12-29 2013-08-13 Kimberly-Clark Worldwide, Inc. Anatomically conforming vaginal insert
US20060270640A1 (en) * 2004-02-18 2006-11-30 Mercian Corporation Method of preventing, medicating, and/or treating hypocalcemia of domestic mammal
EP1768625A2 (en) * 2004-07-09 2007-04-04 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators
US8865200B2 (en) * 2004-07-09 2014-10-21 Laboratoire Hra Pharma Sustained release compositions containing progesterone receptor modulators
EP1768625A4 (en) * 2004-07-09 2008-07-09 Population Council Inc Sustained release compositions containing progesterone receptor modulators
CN101080205B (en) * 2004-07-09 2011-10-12 人口委员会股份有限公司 Sustained release compositions containing progesterone receptor modulators
US20080199511A1 (en) * 2004-07-09 2008-08-21 Laboratoire Hra Pharma Sustained Release Compositions Containing Progesterone Receptor Modulators
EP2246062A1 (en) 2005-07-19 2010-11-03 The Population Council, Inc. Methods and compositions for emergency contraception using endothelin receptor antagonists
US20070254014A1 (en) * 2006-03-20 2007-11-01 Ahmed Salah U Flexible, compressed intravaginal rings, methods of making and using the same, and apparatus for making the same
US20110212155A1 (en) * 2006-03-20 2011-09-01 Ahmed Salah U Flexible, Compressed Intravaginal Rings, Methods of Making and Using the Same, and Apparatus for Making the Same
US8323679B2 (en) 2006-03-20 2012-12-04 Teva Women's Health, Inc. Flexible, compressed intravaginal rings, methods of making and using the same, and apparatus for making the same
US7910126B2 (en) 2006-03-20 2011-03-22 Teva Women's Health, Inc. Flexible, compressed intravaginal rings, methods of making and using the same, and apparatus for making the same
US7824383B2 (en) 2006-06-16 2010-11-02 Family Health International Vaginal drug delivery system and method
US20080051740A1 (en) * 2006-06-16 2008-02-28 Family Health International Vaginal drug delivery system and method
US8741329B2 (en) 2007-09-21 2014-06-03 Merck Sharp & Dohme B.V. Drug delivery system
US20090081278A1 (en) * 2007-09-21 2009-03-26 N.V. Organon Drug Delivery System
EP2244782A4 (en) * 2008-01-25 2011-09-14 Univ Utah Res Found Linear order release polymer
CN101977651A (en) * 2008-01-25 2011-02-16 犹他大学研究基金会 Linear order release polymer
US11413294B2 (en) 2008-02-04 2022-08-16 Ferring B.V. Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
US8580293B2 (en) 2008-02-04 2013-11-12 Teva Women's Health, Inc. Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
US10537584B2 (en) 2008-02-04 2020-01-21 Ferring B.V. Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
US10548904B2 (en) 2008-02-04 2020-02-04 Ferring B.V. Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
EP2359807A1 (en) 2008-02-04 2011-08-24 Teva Women's Health, Inc. Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
JP2011510984A (en) * 2008-02-04 2011-04-07 テバ ウィメンズ ヘルス インコーポレイテッド Monolithic intravaginal rings containing progesterone and methods for their production and use
WO2009099586A2 (en) 2008-02-04 2009-08-13 Duramed Pharmaceuticals, Inc. Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
JP2014167001A (en) * 2008-02-04 2014-09-11 Teva Women's Health Inc Monolithic intravaginal rings comprising progesterone, and manufacturing methods and uses thereof
US20090202612A1 (en) * 2008-02-04 2009-08-13 Ahmed Salah U Monolithic Intravaginal Rings Comprising Progesterone and Methods of Making and Uses Thereof
US9566267B2 (en) 2008-05-20 2017-02-14 Poly-Med, Inc. Biostable, multipurpose, microbicidal intravaginal devices
US9421126B2 (en) 2009-06-03 2016-08-23 Forsight Vision5, Inc. Anterior segment drug delivery
US10004636B2 (en) 2009-06-03 2018-06-26 Forsight Vision5, Inc. Anterior segment drug delivery
US10736774B2 (en) 2009-06-03 2020-08-11 Forsight Vision5, Inc. Anterior segment drug delivery
US8753667B2 (en) 2009-07-21 2014-06-17 The Population Council, Inc. Multi-layered gradient vaginal ring
US20110236462A1 (en) * 2010-03-28 2011-09-29 Shaked Ze Ev Intravaginal drug delivery device
US9937073B2 (en) 2010-06-01 2018-04-10 Forsight Vision5, Inc. Ocular insert apparatus and methods
US8939948B2 (en) 2010-06-01 2015-01-27 Forsight Vision5, Inc. Ocular insert apparatus and methods
US9427400B2 (en) 2010-10-19 2016-08-30 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
JP2013543763A (en) * 2010-11-12 2013-12-09 ザ ユニバーシティ オブ ユタ リサーチ ファウンデーション Intravaginal device for controlled delivery of lubricant
US8715712B2 (en) 2011-09-14 2014-05-06 Forsight Vision5, Inc. Ocular insert apparatus and methods
US10835416B2 (en) 2011-09-14 2020-11-17 Forsight Vision5, Inc. Ocular insert apparatus and methods
US10441534B2 (en) 2012-03-23 2019-10-15 Preglem Sa Method for treating gynecological diseases
EP2641602A1 (en) 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
EP3363500A1 (en) 2012-03-23 2018-08-22 PregLem SA Method for treating gynecological diseases
WO2013140372A1 (en) 2012-03-23 2013-09-26 Preglem Sa Method for treating gynecological diseases
US20160016040A1 (en) * 2012-06-04 2016-01-21 Caryn M. Horsley Medical Exercise Device
US20130324380A1 (en) * 2012-06-04 2013-12-05 Caryn M. Horsley Medical exercise device
US9095744B2 (en) * 2012-06-04 2015-08-04 Caryn M. Horsley Medical exercise device
US9750636B2 (en) 2012-10-26 2017-09-05 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
US10456293B2 (en) 2012-10-26 2019-10-29 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
WO2014167510A2 (en) 2013-04-10 2014-10-16 Preglem Sa Progesteron receptor modulators for use in the therapy of uterine fibroids
US10172869B2 (en) 2013-04-10 2019-01-08 Preglem Sa Progesterone receptor modulators for use in the therapy of uterine fibroids
WO2015055789A1 (en) 2013-10-17 2015-04-23 Bayer Pharma Aktiengesellschaft INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
US11259956B2 (en) 2013-11-14 2022-03-01 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
US11793669B2 (en) 2013-11-14 2023-10-24 The Population Council, Inc. Combination therapy intravaginal rings
US10596103B2 (en) 2013-12-11 2020-03-24 Merek Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
WO2016054002A1 (en) * 2014-09-29 2016-04-07 Yale University Progesterone impregnated vaginal ring/pessary
US11224602B2 (en) 2015-04-13 2022-01-18 Forsight Vision5, Inc. Ocular insert composition of a semi-crystalline or crystalline pharmaceutically active agent
WO2019084469A1 (en) 2017-10-27 2019-05-02 Renovia Inc. Devices, systems, and methods for training pelvic floor muscles
USD935018S1 (en) * 2020-04-07 2021-11-02 The Population Council, Inc. Contraceptive
WO2023200974A1 (en) 2022-04-14 2023-10-19 Yale University Nanoparticles and nanoparticle-releasing vaginal rings

Also Published As

Publication number Publication date
GT196811877A (en) 1970-05-29
GB1252021A (en) 1971-11-03
ES360946A1 (en) 1970-08-01
BR6905338D0 (en) 1973-03-07
JPS5125677B1 (en) 1976-08-02
MY7500059A (en) 1975-12-31
DE1900196A1 (en) 1969-07-31
CH554172A (en) 1974-09-30
CA985173A (en) 1976-03-09
SE369375B (en) 1974-08-26
NL6818655A (en) 1969-07-08
BE726454A (en) 1969-07-03
FR1604934A (en) 1971-05-15

Similar Documents

Publication Publication Date Title
US3545439A (en) Medicated devices and methods
US3920805A (en) Pharmaceutical devices and method
US4012497A (en) Drug excipient of silicone rubber
CA2573266C (en) Sustained release compositions containing progesterone receptor modulators
US4155991A (en) Vaginal ring
US4292965A (en) Intravaginal ring
US4230686A (en) Drug excipient of silicone rubber
CN102497855B (en) Multi-layered gradient vaginal ring
US4888074A (en) Therapeutic rings
AU760302B2 (en) Drug delivery device, especially for the delivery of progestins and estrogens
EP0135283B1 (en) Disposable spermicide-releasing diaphragm
US4344431A (en) Polymeric article for dispensing drugs
KR101592615B1 (en) An intrauterine system
JP2001524124A (en) Vaginal drug delivery device for administration of testosterone and testosterone precursor
IE42345B1 (en) Vaginal ring
US5188835A (en) Intravaginal devices
ZA200103299B (en) Drug delivery device, especially for the delivery of androgens.
DE2259070A1 (en) SOLID PHARMACEUTICAL PREPARATION FORM
IE44736B1 (en) Vaginal ring
Ogle Design, development and optimisation of veterinary intravaginal controlled release drug delivery systems
Nash et al. Nash et al.